BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allen JD, Bishop JR. A systematic review of genome-wide association studies of antipsychotic response. Pharmacogenomics 2019;20:291-306. [PMID: 30883267 DOI: 10.2217/pgs-2018-0163] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Lengyel A, Pinti É, Nebral K, Pikó H, Ujfalusi A, Haas OA, Fekete G, Haltrich I. Chromosome 2q14.3 microdeletion encompassing CNTNAP5 gene in a patient carrying a complex chromosomal rearrangement. J Genet 2021;100. [DOI: 10.1007/s12041-021-01316-z] [Reference Citation Analysis]
2 Crist RC, Vickers-Smith R, Kember RL, Rentsch CT, Xu H, Edelman EJ, Hartwell EE, Kampman KM, Kranzler HR. Analysis of genetic and clinical factors associated with buprenorphine response. Drug Alcohol Depend 2021;227:109013. [PMID: 34488071 DOI: 10.1016/j.drugalcdep.2021.109013] [Reference Citation Analysis]
3 Koromina M, Koutsilieri S, Patrinos GP. Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: implications for clinical pharmacogenomics. Hum Genomics 2020;14:4. [PMID: 31941550 DOI: 10.1186/s40246-019-0254-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Um YH, Kim TW, Seo HJ, Hong SC, Kim SM, Oh JH, Jeong JH. Predictors of 1-year rehospitalization in inpatients with bipolar I disorder treated with atypical antipsychotics. Int Clin Psychopharmacol 2020;35:263-9. [PMID: 32459726 DOI: 10.1097/YIC.0000000000000318] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Yuan R, Li Y, Fu Y, Ning A, Wang D, Zhang R, Yu S, Xu Q. TNIK influence the effects of antipsychotics on Wnt/β-catenin signaling pathway. Psychopharmacology (Berl) 2021. [PMID: 34350475 DOI: 10.1007/s00213-021-05943-3] [Reference Citation Analysis]
6 Wu CS, Luedtke AR, Sadikova E, Tsai HJ, Liao SC, Liu CC, Gau SS, VanderWeele TJ, Kessler RC. Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia. JAMA Netw Open 2020;3:e1921660. [PMID: 32083693 DOI: 10.1001/jamanetworkopen.2019.21660] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Mehta UM, Ibrahim FA, Sharma MS, Venkatasubramanian G, Thirthalli J, Bharath RD, Bolo NR, Gangadhar BN, Keshavan MS. Resting-state functional connectivity predictors of treatment response in schizophrenia - A systematic review and meta-analysis. Schizophr Res 2021;237:153-65. [PMID: 34534947 DOI: 10.1016/j.schres.2021.09.004] [Reference Citation Analysis]
8 Arranz MJ, Salazar J, Hernández MH. Pharmacogenetics of antipsychotics: Clinical utility and implementation. Behav Brain Res 2021;401:113058. [PMID: 33316324 DOI: 10.1016/j.bbr.2020.113058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Li W, Su X, Chen T, Li Z, Yang Y, Zhang L, Liu Q, Shao M, Zhang Y, Ding M, Lu Y, Yu H, Fan X, Song M, Lv L. Solute Carrier Family 1 (SLC1A1) Contributes to Susceptibility and Psychopathology Symptoms of Schizophrenia in the Han Chinese Population. Front Psychiatry 2020;11:559210. [PMID: 33173509 DOI: 10.3389/fpsyt.2020.559210] [Reference Citation Analysis]